Skip to main content
SciBX: Science-Business eXchange
As published Thursday, December 11, 2014

  • Cover Story: Universal reversal for heparin

    By Kai-Jye Lou, Senior Writer

    Titrating heparin treatment is a balancing act for hematologists trying to control blood coagulation without causing excessive bleeding. A synthetic heparin reversal agent from The University of British Columbia uses a dendritic polymer to neutralize the anticoagulant and could provide a lower-risk option for preventing bleeding during surgery than protamine, the standard of care.1 The challenge will be finding an industry partner to help move the candidate into clinical trials.

    Protamine is the only approved antidote for heparin-based therapies. The cationic peptide works by binding to heparins, which are negatively charged, to form a complex that lacks anticoagulant activity. However, protamine has a narrow therapeutic window, has an unpredictable dose response and can cause significant adverse effects including a sudden drop in peripheral blood pressure, pulmonary hypertension and bradycardia.

    Full Article
  • Terazosin reborn

    Chinese researchers have found that the generic alpha-blocker terazosin prevents apoptosis and want to pursue it for stroke, but they will need to navigate a landscape of difficult preclinical models.

  • PIEZO de resistance

    A Duke team has found a new role for PIEZO calcium channels in cartilage damage, suggesting channel inhibitors could be developed for joint injury or osteoarthritis.

  • Lysin in wait

    Micreos and ContraFect are separately developing phage lysins, which are not prone to bacterial resistance, as complements to antibiotics.


  • This Week in Techniques

    Controlling Plasmodium falciparum gene expression to identify new malaria targets; using gp130-expressing mice as models of MM; diagnosing familial cold autoinflammatory syndrome with an NLRC4 mutation; and more...

  • more techniques news
Subscribe Now
Free Trial